CareDx's AI-Powered AlloHeme Test Detects AML and MDS Relapse 41 Days Earlier Than Standard Methods
核心洞察
CareDx announced successful clinical validation of AlloHeme (搜索), an AI-powered blood test that identifies cancer relapse in AML and MDS patients following allogeneic hematopoietic cell transplant with 85% sensitivity and 92% specificity.
The ACROBAT study demonstrated that AlloHeme (搜索) detected relapse a median of 41 days earlier than clinical detection, with patients showing positive results having a 12-fold higher relapse risk at 6 months post-transplant.
The non-invasive NGS-based surveillance solution is expected to launch commercially in the U.S. in 2027 as part of CareDx's expansion into cell therapy and hematologic malignancy markets.
CareDx has announced pivotal clinical validation results for AlloHeme (搜索), the first artificial intelligence-powered next-generation sequencing surveillance test designed to predict relapse in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) following allogeneic hematopoietic cell transplant (HCT). The non-invasive, blood-based monitoring solution demonstrated superior performance compared to traditional bone marrow-based methods, identifying cancer relapse significantly earlier than current standard of care approaches.
Clinical Performance Results
The ACROBAT study (NCT04635384), a prospective, multi-center observational trial conducted across 11 U.S. transplant centers, evaluated 198 subjects over 24 months with 40 relapse events. AlloHeme (搜索) demonstrated robust clinical performance with 85% sensitivity and 92% specificity, translating to a 95% negative predictive value, 79% positive predictive value, and an area under the curve of 0.89.
The test identified relapse a median of 41 days before clinical detection, providing clinicians with a crucial early warning system. At 6 months post-transplant, patients with positive AlloHeme (搜索) results showed a 12-fold higher relapse risk compared to patients with negative results (p<0.001). The assay also demonstrated greater sensitivity and lead time than traditional standard of care testing, including more invasive bone marrow and multi-parameter flow cytometry (MFC-MRD), as reported by participating clinical trial sites.
Addressing Critical Clinical Need
"Cancer relapse remains a leading cause of mortality in patients with AML and MDS post allogeneic hematopoietic cell transplantation," said Dr. Jeff Teuteberg, CareDx Chief Medical Officer. "AlloHeme (搜索) represents the next wave of innovation within CareDx's Transplant+ strategy as we expand from solid organ transplantation into cell therapy, by providing clinicians with a highly sensitive, blood-based tool that can help identify relapse earlier."
Dr. Ran Reshef, Professor of Medicine at Columbia University and Director of Translational Research for the Blood and Marrow Transplantation Program, emphasized the clinical significance: "These data represent an important step forward in relapse surveillance for AML and MDS. AlloHeme (搜索) offers a simple, effective strategy to identify high-risk patients early, potentially opening the door for preemptive interventions to prevent relapse and improve survival."
Strategic Market Expansion
The introduction of AlloHeme (搜索) represents a significant milestone in CareDx's Transplant+ strategic expansion into the cell therapy and hematologic malignancy market, where AML and MDS currently lack a highly sensitive and universally applicable commercial molecular monitoring solution. This ultra-sensitive, tumor-naive surveillance approach addresses a major gap in post-HCT relapse monitoring for AML and MDS patients, broadening CareDx's impact beyond solid organ transplantation into areas of growing clinical need.
CareDx's Transplant+ strategy includes developing a comprehensive suite of molecular tools for cell therapy, hematology, and oncology that span allogeneic HCT relapse detection and chimeric antigen receptor T-cell therapy (CAR-T) persistence monitoring.
Commercial Timeline
CareDx anticipates a sequenced U.S. launch of AlloHeme (搜索) beginning with CLIA readiness in 2026, followed by commercial introduction in 2027 and payer coverage anticipated in 2028. The test will be offered alongside CareDx's full suite of patient and digital solutions for the cell therapy community, leveraging the company's established precision medicine platform.